Literature DB >> 8492844

Stereotactic radiosurgery of cavernous sinus meningiomas as an addition or alternative to microsurgery.

C M Duma1, L D Lunsford, D Kondziolka, G R Harsh, J C Flickinger.   

Abstract

To evaluate the response of cavernous sinus meningiomas to stereotactic radiosurgery, we reviewed our 54-month experience with 34 patients. All patients underwent radiosurgery with a 201-source cobalt-60 gamma unit. Twenty-eight patients (82%) had previous histological confirmation of a meningioma (1 to 5 cranial base craniotomies per patient); 6 (18%) were treated on the basis of neuroimaging criteria alone. The single-fraction radiation tumor margin dose (10 to 20 Gy) was designed to conform to the irregular tumor volumes in all patients. The maximum radiation dose to the optic nerve or tract was reduced to 9 Gy in 31 patients. No patient had tumor growth (100% tumor control) during the follow-up interval (median, 26 mo). Tumor regression was observed in 56% of patients imaged at an average of 18 months. Eight patients (24%) improved clinically at follow-up examinations. Four patients developed new or worsened cranial nerve deficits during the follow-up interval; two had subsequent full improvement. No patient developed an endocrinopathy or new extraocular muscle paresis. Stereotactic radiosurgery, using multiple isocenter dosimetry facilitated by the gamma unit, is an accurate, safe, and effective technique to prevent the growth of tumors involving the cavernous sinus. Despite the proximity of such tumors to adjacent cranial nerves, complications were rare. The maximum length of hospital stay was 36 hours, and all patients returned to their preoperative employment status within 3 to 5 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8492844     DOI: 10.1227/00006123-199305000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  26 in total

1.  Radiosurgery of meningeal melanocytoma.

Authors:  H Kurita; H Segawa; M Shin; K Ueki; S Ichi; T Sasaki; M Tago; T Kirino
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 2.  Parasellar syndromes.

Authors:  Janine L Johnston
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 3.  Linac radiosurgery as a tool in neurosurgery.

Authors:  R Deinsberger; J Tidstrand
Journal:  Neurosurg Rev       Date:  2005-02-22       Impact factor: 3.042

4.  Treatment of cavernous sinus tumors with linear accelerator radiosurgery.

Authors:  S D Chang; J R Doty; D P Martin; S L Hancock; J R Adler
Journal:  Skull Base Surg       Date:  1999

5.  Surgical Management of Tumors Involving Meckel's Cave and Cavernous Sinus: Role of an Extended Middle Fossa and Lateral Sphenoidectomy Approach.

Authors:  Daniel Q Sun; Arnold H Menezes; Matthew A Howard; Bruce J Gantz; David M Hasan; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2018-01       Impact factor: 2.311

Review 6.  Long term experience of gamma knife radiosurgery for benign skull base meningiomas.

Authors:  W Kreil; J Luggin; I Fuchs; V Weigl; S Eustacchio; G Papaefthymiou
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

7.  European Society for Stereotactic and Functional Neurosurgery. Abstracts selected for presentation at the 11th Congress. Antalya, Turkey, September 24-27, 1994.

Authors: 
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Use of sodium fluorescein in skull base tumors.

Authors:  Carlos Eduardo da Silva; Jefferson Luis Braga da Silva; Vinicius Duval da Silva
Journal:  Surg Neurol Int       Date:  2010-10-30

9.  Radiotherapy for meningiomas.

Authors:  M H Maor
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

10.  A prospective study of cavernous sinus surgery for meningiomas and resultant common ophthalmic complications (an American Ophthalmological Society thesis).

Authors:  Steven Newman
Journal:  Trans Am Ophthalmol Soc       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.